Mandatory VTE assessment hit 95% compliance. National outcome data tell a different story.

Quality improvement · NHS · Venous thromboembolism

Mandatory VTE assessment hit 95% compliance. National outcome data tell a different story.

Scope of this post: This article is about the assessment-based process — how it was mandated, measured, and rewarded — and why national data suggest it did not deliver the guideline's stated aim. It is not an argument against thromboprophylaxis itself; that is a separate clinical question, covered in a follow-up post.

In June 2010, England launched one of the most ambitious patient-safety programmes in its recent history. Every adult admitted to an NHS hospital would receive a documented assessment of venous thromboembolism (VTE) risk. Thromboprophylaxis would follow for those who needed it. Trusts would report compliance quarterly. Financial penalties would bite if performance fell short. NICE had already published its guideline — CG92 in January 2010 — setting out what good prevention looked like. The aim was clear: reduce deep vein thrombosis (DVT), pulmonary embolism (PE), and the deaths that follow from hospital-associated thrombosis.

Fifteen years on, the compliance charts look like a quality-improvement textbook. National assessment rates climbed from roughly 53% in mid-2010 to above 90% within two years. From April 2013, when the target was raised to 95%, the NHS met it and kept meeting it — quarter after quarter, trust after trust. By 2019, the figure sat at 95–96% and barely moved. On paper, the programme worked.

But paper is the problem.

The wrong scoreboard

The NHS did not make thromboprophylaxis mandatory in the abstract. It made documented risk assessment mandatory — and then treated assessment completion as the primary measure of national success. CQUIN payments, standard-contract clauses, and board-level dashboards all converged on one question: was the form filled in?

That is a process metric — not whether the right patient received prophylaxis, whether doses were administered, or whether fewer patients developed clots. Root-cause analysis was part of the policy bundle, but compliance with assessment drove behaviour and reputation.

When a system optimises for what it measures, it should surprise no one when the measurement diverges from the outcome.

HES tells a different story

Hospital Episode Statistics (HES) do not record "hospital-acquired DVT" as a discrete field. What they do record — reliably, at national scale, year on year — is whether a DVT code appeared as a secondary diagnosis on an admission episode whose primary reason for hospital contact was something else. That is an imperfect proxy. It may include some pre-existing clots. It will miss silent events never coded. It cannot distinguish community DVT from thrombosis provoked by the index admission.

It is, nonetheless, the closest thing we have to a ten-year national signal of DVT arising in the context of hospital care — and that signal is not comforting.

Secondary DVT rate (England, HES)

Period	Per 100,000 episodes
2012/13	~166
2019/20	~210
2021/22	~225
2020/21 (COVID)	~253

Source: Hughes et al., BMJ Open 2025. SPC analysis shows significant upward trend from 2013 — when assessment compliance was already above 95%.

That is a red flag. It is proof that the assessment-based process the NHS built around the guideline — mandatory forms, compliance targets, central returns — did not produce the epidemiological pattern you would expect if that process were reliably reducing hospital-context DVT at scale. The failure lies in what was industrialised, not in the existence of thromboprophylaxis as a clinical intervention.

Compliance up. Secondary DVT coding up.
Those two lines were never supposed to run together.

The death data make it worse

If the assessment process were reliably triggering effective prevention among the patients the programme was designed to protect, we should see that in hospital-linked VTE mortality — deaths in hospital or within 90 days of discharge among people with a recent admission, with VTE on the death certificate. That is NHS Outcomes Framework indicator 5.1 (I00675), the official national outcome measure aligned with NICE's hospital-associated thrombosis framing.

Here the official narrative and the epidemiology part company.

The published story (rate) 72.8 → 62 Fatal VTE per 100,000 admissions 2007/08 to 2019/20 (61.2 in 2023/24) ✓ Widely cited as success

The epidemiology (count) 8,106 → 9,087 Absolute hospital-linked VTE deaths 2007/08 to 2019/20 (+12% pre-COVID) ↑ Significant upward SPC trend from 2013

The rate fell because the denominator grew faster than the numerator — adult hospital admissions increased by roughly a third over the same period — not because England was clearly putting fewer people in the ground from hospital-associated thrombosis.

A metric that dilutes the truth

Why does a falling rate mislead so convincingly? Because NHS OF 5.1 spreads fatal events across a denominator far broader than the population where those deaths actually occur.

National linkage work by Catterick et al. (BMJ Open, 2024), using the same case definition as the outcomes-framework indicator, found that 86% of hospital-linked fatal VTE followed emergency inpatient admission. Planned inpatient and day-case pathways together accounted for only about 12% of deaths — yet they form a large share of all admitted activity.

The indicator dilutes high-mortality emergency pathways across millions of lower-risk admissions.
A rate can fall while the count of people dying does not — and even rises.

Day cases are included in both numerator and denominator of OF 5.1, so a day-case surge could artefactually lower the rate. HES data rule that out: day cases rose in number but held at about one-third of activity for over a decade. Fatal VTE stayed anchored in emergency inpatient care. The problem is a rate-based metric on a heterogeneous admission base, sold on the promise of fewer clots and fewer deaths.

Well meaning guideline failed in practice

NICE CG92 — later updated as NG89 — describes a pathway: identify risk, prescribe appropriate thromboprophylaxis for those who need it, consider post-discharge extension where indicated, investigate incidents, learn from harm. That is more than a tick-box.

What England actually mandated and measured was the first step — documented VTE risk assessment — and treated completion of that step as if it stood for the whole pathway. Form completion, central reporting, and a 95% compliance target became the national product. Thromboprophylaxis remained in the guideline text; it did not become the national scoreboard.

That substitution is why I regard the guideline as well meaning but failed in practice: not because prevention is futile, but because the assessment-based process given statutory force was the wrong proxy for it.

Process–outcome decoupling

Metric	What happened	Signal
VTE assessment compliance	Target met, sustained, celebrated	✓
HES secondary DVT	Upward trend through compliance era	↑
Fatal VTE (absolute deaths)	Flat to rising from 2013; SPC significant	↑
Fatal VTE (published rate)	Modest decline; cited as success	↘

We optimised documentation and called it prevention.

What should change

Assessment completion should be a gateway metric, not the finish line. Outcomes would be tracked in absolute terms and pathway-specific strata — emergency medical admissions first — with prophylaxis administration audited alongside forms. Secondary DVT in HES would be monitored as a sentinel, coding caveats acknowledged but not deployed to dismiss the signal.

The lesson generalises beyond thrombosis. When a guideline becomes mandatory NHS activity with financial teeth, ask which part of the pathway was actually enforced. If the answer is a single process step — here, risk assessment — you may get excellent compliance on that step and no superior clinical outcome on the harm the guideline was written to prevent.

Coming next: Thromboprophylaxis on its own terms — evidence, delivery, and outcomes. This post stops where the national programme stopped measuring: at the form.

The clinical intention was humane. The assessment-based architecture was not equal to it.

References

1. NICE. Venous thromboembolism in over 16s (NG89). nice.org.uk/guidance/ng89
2. NICE. VTE: reducing the risk for patients in hospital (CG92). nice.org.uk/guidance/cg92
3. Department of Health. Report of the Independent Expert Working Group on Prevention of VTE. 2007.
4. NHS England / NHS Digital. VTE risk assessment quarterly data and CQUIN specifications, 2010–2020.
5. Catterick MD, Hunt BJ. Impact of the national VTE risk assessment tool in secondary care in England. Blood Coagul Fibrinolysis. 2014;25(6):631–635.
6. Hughes F, et al. HES DVT/PE trends. BMJ Open. 2025. doi:10.1136/bmjopen-2024-090301
7. Catterick MD, et al. Who dies from VTE after hospitalisation in England? BMJ Open. 2024. doi:10.1136/bmjopen-2023-078898
8. NHS England Digital. NHS Outcomes Framework 5.1 (I00675). Feb 2025 release
9. Nuffield Trust. Blood clots following hospital care. nuffieldtrust.org.uk
10. NHS England Digital. Hospital Admitted Patient Care Activity (HES). digital.nhs.uk
11. Hunt BJ, et al. VTE prevention: UK experience. Res Pract Thromb Haemost. 2023. PMC9903667

Hernia - what you are told, what it is and how to understand it

 

INGUINAL HERNIA

What you are told, what it is and how to understand it 

A patient reads on the British Hernia Society website that after groin hernia surgery the hernia coming back is “about 1 in 200.” A trainee cites a mesh trial: 2–3% at five years. International guidelines and registry reviews speak of population-level reoperation burden in a different register again.

Meanwhile, year after year, English Hospital Episode Statistics (HES) and Scottish SMR data show that roughly one in ten to fourteen inguinal hernia operations is coded as repair of a recurrent hernia — a proportion that has moved only slightly since the early 1990s.

None of these figures is fabricated. They answer different questions. The problem is that we quote the low ones in clinic and run the list from the high ones in theatre, without joining them up. Recurrence is discussed as if it were solved in the mesh era; recurrent groin hernia repair remains ordinary NHS work.

Study of Surgery vs. Practice of Surgery

In 2010, I wrote to The Surgeon about a Scottish paper on laparoscopic inguinal hernia and unequal access — the “postcode lottery.” Fair topic. But the same Information Services Division (ISD) tables showed recurrent repairs (OPCS T21) making up about 9% of Lothian’s inguinal workload versus 6.4% elsewhere, while the discussion leaned on literature with far lower recurrence.

I asked whether laparoscopic adoption had actually reduced, in real theatre terms, the volume of recurrent operations; whether a training centre paid a learning-curve price; and why operational figures sat so awkwardly beside published science.

The Core Disconnect: The study of surgery and the practice of surgery are simply not the same activity.

Phillips and Goldman, in the 1994 Health Care Needs Assessment volume, already used English HES for 1995/96: 6,328 recurrent repairs among 87,651 inguinal operations — 7.2%. They noted that the true recurrence rate would be higher still, because many patients never return for reoperation. The BMJ clinical review for 2001/02 England gave almost the same picture: about 7% recurrent among all inguinal activity.

Mesh became standard; laparoscopy was mandated for bilateral and recurrent cases; patient information moved toward half a percent. Yet, the administrative share of recurrent repair work did not disappear.

Understanding the 7% Metric

That 7% is not "every primary mesh repair fails at 7%." It means: among all inguinal hernia operations recorded in a year, what fraction is coded recurrent?

The mix includes:

• Late failures

• Re-recurrent groins

• Symptomatic re-presentation

• Referral patterns and coding quirks

It is nonetheless what theatres, coders, waiting lists, and trainees live with.

Region / Study	Reported Metric	Actual Workload Share / Reality
Wales (2004–2019)	~4% reoperation for recurrence with mesh	Yearly recurrent-operation shares still touched 8% in some years.
Southeastern Scotland	Rose-tinted expectations	Recurrent repair’s share of activity fell from 11.7% to 8.8% as mesh rose — improvement, not alignment with “1 in 200.”
European Registries (Herniamed)	RCT numerators	11–14% of inguinal repairs in men are recurrent cases.

HerniaSurge and society guidance rightly cite lifetime and population burden; that is consistent with administrative data, not with telling an elective primary patient their personal risk is half a percent without context.

Scotland’s nineteen-year ISD cohort (Ramsay et al.) is often cited to “prove” low modern recurrence: ~1.8% reoperation after open primary and ~3.6% after laparoscopic primary. Those are real, linked, population answers — and both can be true alongside a ~7% recurrent-operation mix on the annual list. One measures index primary failure over time; the other measures what fraction of today’s workload is recurrent repair. Conflating them is how we reassure boards while recurrent groin hernia still fills the Friday slot.

Follow-Up We Do Not Do

Trials and registries with structured follow-up produce the 1–3% band we teach for viva and consent. The NHS, especially after day-case expansion, does not routinely follow primary inguinal repairs in a way that would verify those numerators. Many recurrences are managed in primary care, tolerated, or never reoperated.

Administrative reoperation understates symptomatic failure (Phillips and Goldman said so explicitly) while trials in selected centres may overstate how uniformly good “standard mesh repair” is when dispersed across low-volume general lists.

We therefore cannot treat trial 1–3% as the verified national outcome of primary repair without follow-up. The honest signals we already have are operational:

1. Recurrent repair as a share of activity.

2. Linked reoperation after primary in national cohorts.

3. Proxies that cluster with later failure (when we bother to look).

Hernia is Still Not Its Own Specialty

I am told to blame “the system.” The system, though, is thousands of consultants for whom an inguinal hernia can be done irrespective of main subspecialty — colorectal, vascular, endocrine — with a handful of cases a year, no personal recurrence rate on the dashboard, and no obligation to report it. Planned colonic cancer resection is not distributed that way. Hernia is treated as a procedure anyone can do on the side, not a pathway where best-in-class outcomes are demanded.

That is not a claim that every colleague is careless. It is a claim about professional norms: low volume, mixed techniques, and recurrent cases on the trainee list while primaries are quoted at trial rates.

• German Routine Data (AOK): Link low hospital hernia volume to higher recurrence-operation risk.

• Shouldice Hospital (Ontario): Reports a ~1.15% reoperation rate in that institution versus ~5% in general hospitals. This is less a sermon on suture than on volume, standardized technique, and a rigorous follow-up culture — a hernia factory with audit versus a hernia slot on a general list.

The College and the British Hernia Society have pushed registry and guideline work. The gap is mandatory local reporting tied to the same OPCS codes we already bill — primary failure where we can measure it, and recurrent share of activity every trust already generates but rarely publishes beside the leaflet number.

Proxies When the Numerator is Missing

If we will not follow patients, we should at least use the associations the data already show:

• Volume: There is an inverse relationship with recurrence/reoperation in several large database studies. This is worth an audit, not moral theatre.

• Early Morbidity and Later Recurrence: Bouras et al. linked English HES and primary care (CPRD) for primaries between 1997 and 2012. A 30-day wound infection or bleeding was followed by later surgery for recurrence in 3.2% versus 1.7% without those complications ($p < 0.05$). For laparoscopic repair, the adjusted odds ratio was about 8; for open repair in the same study, the association did not reach conventional significance.

• Timing: Swedish register work and German quality-indicator reviews separate early reoperations (often haematoma, infection, pain) from later reoperation for recurrence; both matter, but they are not the same event. 30-day readmission alone is a weak long-term recurrence proxy. Repair-related early theatre return is a sharper warning flag.

Note on Chronic Pain: Chronic groin pain follows a parallel story (often ~10–15% in pooled series, far above “1 in 200”). Recurrence and pain are not interchangeable, but they share a pattern: conference outcomes are significantly kinder than primary-care reality.

What Would "Honest" Look Like?

• Publish both metrics by trust and year: reoperation/recurrence after defined primary repair where linkage allows it, and recurrent repair as a % of all inguinal activity (T21 / T20+T21).

• Stop conflating them in consent, leaflets, and board papers.

• Audit repair-related 30-day theatre return and complications as risk flags, not as substitutes for follow-up.

• Treat recurrent inguinal hernia as difficult index work — requiring specific technique, volume, and a named surgeon — not list filler.

• Treat hernia as work that deserves the same outcome discipline we expect elsewhere in elective general surgery.

The Honest Consent Conversation

Honest consent for an elective primary might sound like this:

"In good published studies of mesh repair, reoperation for recurrence is often a few per cent over five to ten years, but we do not routinely follow you to confirm that; national hospital data show repair of a previously operated groin still accounts for roughly one in ten inguinal operations; if you have a serious early problem after surgery — especially if you return to theatre — that has been linked to a higher chance of later recurrence. Your surgeon’s volume and whether this is their main work matter."

That is longer than “1 in 200.” It is also the conversation that closes the gap between study and practice.

Until we measure and publish what the list already knows, we will keep pretending recurrence has “come down” because trials improved, while HES and theatre registers tell the same stubborn story since Phillips and Goldman’s 7.2%: recurrent groin hernia repair remains ordinary NHS work, not a rarity. It remains a procedure we allow anyone to do, without demanding the outcomes we quote.

If your trust measured inguinal activity last year, what fraction was coded recurrent — and when did you last see that number beside your unit’s quoted primary recurrence rate?

References

1. British Hernia Society. Groin hernia and you. Link

2. Phillips W, Goldman M. Groin hernia. In: Stevens A, Raftery J, eds. Health Care Needs Assessment. First Series. Oxford: Radcliffe; 1994.

3. Jenkins JT, O’Dwyer PJ. Inguinal hernias. BMJ 2008;336:269–272. doi:10.1136/bmj.39450.428275.AD

4. Hemadri M. Letter: Variation of laparoscopic hernia repair in Scotland. The Surgeon 2011;9:58–59. doi:10.1016/j.surge.2010.06.010

5. Stevenson AD et al. Variation of laparoscopic hernia repair in Scotland. The Surgeon 2010;8:140–143. doi:10.1016/j.surge.2009.11.001

6. Ramsay G, Scott NW, Jansen JO. Reoperation for recurrence after laparoscopic and open inguinal hernia repair. Hernia 2020;24:793–800. doi:10.1007/s10029-019-02073-w

7. Bouras G et al. Impact of short-term complications on recurrence (linked HES/CPRD). Hernia 2017. doi:10.1007/s10029-017-1575-1

8. Köckerling F et al. Surgical risk factors for recurrence — review. Innov Surg Sci 2017. PMC6754004

9. Köckerling F et al. Hospital volume and outcome in inguinal hernia repair (AOK). Surg Endosc 2020. PMC7395912

10. HerniaSurge Group. International guidelines for groin hernia management. Hernia 2018. doi:10.1007/s10029-018-1799-9

11. Malik A et al. Reoperation for inguinal hernia repair in Ontario. Can J Surg 2016 (Shouldice ~1.15% vs ~5% general hospitals). PMC4734914

12. Atkinson HDE et al. Southeastern Scotland cohort 1985–2001. BMJ 2004;329:1315–1316. PMC534839

The Price of Understaffing: What UK Healthcare Outcomes Really Tell Us

From workforce gaps and wage suppression to avoidable deaths, delayed cancer diagnoses, record waiting lists and a £60 billion negligence liability — a data-driven examination of consequence.

📊 Operational data | OECD, NHS Resolution, Nuffield Trust    🌍 UK vs Scandinavia vs Western world    📅 2024–2025 figures

This is the third post in a three-part series. If you haven’t read the first two, the argument builds on their foundations:

Part 1 → UK healthcare staff: fewer in number and lower paid than comparable countries

Part 2 → Where does the NHS spend the £60bn it saves on staffing? Non-staff costs examined

In the first two posts in this series we established two uncomfortable truths. First, the UK has significantly fewer doctors and nurses per capita than comparable high-income nations, and pays them less. Second, the money not spent on staff doesn’t disappear — it ends up absorbed by non-staff costs: pharmaceuticals, management consultancies, PFI financing, administration, and IT procurement at a premium. The staffing gap between the NHS and comparable Scandinavian systems is up to £60 billion per year.

In this third post we ask the most important question of all: what does that gap cost patients?

We examine five major outcome domains — avoidable mortality, clinical outcomes for cancer, heart attack and stroke, elective surgery waiting times, clinical negligence costs, and temporary staffing expenditure — and look at what the operational data (not trial data) tells us about statistical correlation with staffing levels.

---

1. Avoidable Mortality: Deaths the System Should Have Prevented

Avoidable mortality is split into two components. Preventable mortality reflects failures of public health upstream. Treatable mortality — deaths that should not have occurred with timely, effective clinical intervention — is the sharpest and most relevant mirror for health system performance, because it isolates what healthcare itself can and should prevent.

The Nuffield Trust’s analysis of OECD data shows that the UK’s treatable mortality rate was 71 per 100,000 population in 2019 — above that of seven Western European comparator countries for which data was available that year. In this measure, a higher number means more deaths — more people whose lives the healthcare system should have saved but did not.

Country	Treatable deaths / 100,000	Year	vs UK
Switzerland	~39	2021	Better (−45%)
Australia	49	2022	Better (−31%)
Nordic countries (Sweden, Norway, Denmark)	Below UK	2021–22	Consistently better — lowest-mortality quartile across OECD
4 further W. European nations	Below UK	2019	All outperform UK (Nuffield Trust / OECD)
UK	71	2019	Above 7 of its Western European peers
OECD average	79	2021	UK below average only because E. European countries raise it
United States	95	2022	Worst among comparable high-income nations
Sources: Nuffield Trust/OECD (2024); OECD Health Statistics. Age-standardised, deaths under 75. Higher = worse.

The UK at 71 sits below the OECD average of 79 only because that average is pulled upward by Eastern and Southern European countries with significantly weaker healthcare systems. Against its genuine peer group — France, Germany, the Netherlands, Belgium, Switzerland, Australia, and the Nordic nations — the UK performs poorly. The difference is in healthcare capacity and staffing levels.

Statistical Significance Note

A peer-reviewed cross-national panel study using OECD data across 26 countries found that a 1% increase in nurse-staffing density reduces 30-day mortality from heart attack by 0.65%, from haemorrhagic stroke by 0.60%, and from ischaemic stroke by 0.80%. Sweden and Denmark had the highest simulated reductions in overall HCQI mortality from their nursing levels (−3.53 and −3.31 respectively).

Source: Labbé et al. (2018) — 26 OECD countries, 2005–2015.

---

2. Cancer Care: Survival Rates That Lag Behind Our Neighbours

The most recent EUROCARE-6 data analysed across 29 European countries reveals a consistent pattern: Nordic countries dominate the top of survival tables across most major cancers, while the UK is near or below average for its income group.

Cancer Type	Sweden	Norway	Denmark	UK	EU-24 Avg.
Ovarian (5-yr)	46.5%	45%+	–	36.2%	39.2%
Lung (5-yr)	19.5%	19.0%	–	13.3%	~15–16%
Melanoma (5-yr)	87%+	87%+	87%+	~83%	83%
Pancreatic (5-yr)	~10–12%	~10–12%	~10–12%	6.8%	~9%
Sources: EUROCARE-6 (De Angelis et al., 2024); EU Country Cancer Profiles Synthesis Report 2025 (OECD/EU). Five-year relative survival rates.

For ovarian cancer, Sweden records 46.5% five-year survival compared to the UK’s 36.2% — a gap of over ten percentage points that directly translates to lives lost. For lung cancer the UK at 13.3% is significantly below Sweden (19.5%) and Norway (19.0%).

“Survival was persistently higher in Australia, Canada, and Sweden, intermediate in Norway, and lower in Denmark, England, Northern Ireland and Wales, particularly in the first year after diagnosis and for patients aged 65 and older.” — International Cancer Benchmarking Partnership, Lancet, 2011

---

3. Heart Attack and Stroke: Where Every Minute — and Every Nurse — Counts

A landmark study using nationwide registry data — 87 Swedish hospitals (119,786 patients) and 242 UK hospitals (391,077 patients), 2004–2010 — found that 30-day mortality from AMI was lower in Swedish hospitals (8.4%) than UK hospitals (9.7%).

Sweden — AMI 8.4% 30-day case-mix adjusted mortality

UK — AMI 9.7% 30-day case-mix adjusted mortality — and higher variation between hospitals

That 1.3 percentage point difference translates to thousands of preventable deaths annually across 100,000+ AMI admissions per year.

Statistically Significant Correlation: Staffing → Acute Mortality

At the ward level in the English NHS, a retrospective longitudinal study of 66,923 admissions found a statistically significant association between registered nurse fill-rate and in-hospital mortality (OR 0.9883, 95% CI 0.9773–0.9996, p=0.0416). An extra 12-hour shift by an RN was associated with a 9.6% reduction in the odds of a patient death.

Critically, there was no statistically significant association for healthcare support workers or agency nurses — meaning agency staff are not effective substitutes for permanent, ward-familiar RNs.

Source: Propper et al., BMJ Quality & Safety 2023; Dall’Ora et al., JAMA Network Open 2024.

---

4. Elective Surgery Waiting Times: A Crisis Within a Crisis

As of late 2025, 7.3 million elective procedures were on the NHS waiting list in England. Only 62% of patients were waiting less than 18 weeks — far below the 92% constitutional standard. For orthopaedic procedures:

NHS — Hip Replacement 24–28 wks Average wait 2025 (pre-pandemic: 12–13 weeks)	NHS — Knee Replacement 28–29 wks Average wait 2025 (pre-pandemic: ~13 weeks)
Spain, Finland, Italy ~Pre-covid Hip/knee wait recovery broadly on track by 2023	UK vs Peers 50% longer England’s median hip wait still 50% longer than pre-2020

“England has fewer hospital beds, lower numbers of key staff and lower levels of investment in buildings and equipment than many other high-income countries — and this is likely to have affected how quickly the millions of people waiting can have the surgery they need to live comfortably.” — Nuffield Trust, 2024 analysis of OECD Health Statistics

Countries with more staff, more beds, and better-paid permanent workforces recovered more quickly because they had more capacity to absorb the backlog. England entered the pandemic with structural vulnerabilities — the same ones documented in Parts 1 and 2 of this series — and those vulnerabilities have defined the pace of recovery.

---

5. Clinical Negligence: The Hidden Fiscal Iceberg

Metric	Figure	Trend
Annual claims paid (2024/25)	£3.1 billion	+10% year-on-year
Annual claims paid (2023/24)	£2.8 billion	+6.8% on prior year
Annual claims paid (2006/07, real terms)	£1.1 billion	Baseline — 182% real-terms increase since
“Cost of harm” estimate (CNST, 2024/25)	£4.6 billion	Wider measure
Total provision for future liabilities (March 2025)	~£60.0 billion	2nd largest government balance sheet liability
Maternity-related liabilities (since 2019)	£27.4 billion	52% of annual pay-outs relate to obstetrics
New claims filed (2024/25)	14,428	+5% — exceeds pre-pandemic peak

⚠️ KEY FINDING: The £60 billion total negligence liability is not primarily a legal or administrative failure. It is a patient safety failure. Patient safety failures are systematically linked in the operational literature to inadequate staffing, high use of temporary staff, and overworked permanent staff — precisely the conditions documented in Part 1 of this series.

---

6. Agency and Temporary Staff Spend: The Vicious Cycle

The NHS’s reliance on agency staffing is the most direct and visible financial consequence of the workforce shortages described in Part 1. The cycle is self-reinforcing and extremely expensive.

1 Workforce undersupply + below-market pay113,000 NHS vacancies at peak; nurse pay 20–30% below comparable economies

↓

2 Staff leave permanent NHS roles or reduce hoursBurnout, industrial action 2022–24, and active resignation-to-agency arbitrage

↓

3 Trusts pay premium agency rates to fill rotasUp to £2,000 per nursing shift; total spend peaked at £3.5bn (2022/23)

↓

4 Quality of care deteriorates — agency ≠ permanent RNAgency nurses do not reduce mortality risk equivalently to permanent RNs (Propper et al. 2023)

↓

5 Clinical incidents, complaints and negligence claims rise14,428 new clinical negligence claims in 2024/25 — 5% above pre-pandemic peak

↓

6 Budget consumed; less available for permanent staffing investment£3.1bn negligence pay-outs + £2.07bn agency spend = over £5bn diverted from patient care annually

---

7. The Statistical Case: Connecting Staffing Inputs to Outcome Outputs

The six outcome domains above are connected through a common mechanism: the ratio of appropriately trained, well-supported, permanent clinical staff to patients in need. The operational evidence base for this relationship is extensive and consistent in direction.

Key operational evidence points (all statistically significant):

OECD: Nurse staffing → AMI/Stroke mortality	1% increase in nurse density → 0.65% reduction in AMI 30-day mortality; 0.80% reduction in ischaemic stroke mortality. Analysis of 26 OECD countries 2005–2015.
NHS England: RN fill-rate → inpatient mortality	Extra 12-hour RN shift: 9.6% reduction in odds of patient death (OR 0.9044; p=0.0416). No equivalent effect for healthcare support workers or agency nurses. Study of 66,923 admissions, 53 wards, 2017.
Multidisciplinary staffing → hospital mortality	Hospitals with lower medical and AHP staff had 4% higher mortality rates (RR 1.04; 95% CI 1.02–1.06). Pooled finding from a systematic review (Dall’Ora et al., 2023).
Temporary staffing → mortality risk not fully mitigated	626,313 patient admissions (JAMA Network Open, 2024): days of low nurse staffing, even when remedied by temporary staff, carried elevated mortality risk compared to adequate permanent staffing.
Nuffield Trust: Structural vulnerabilities → slow elective recovery	Across 10 high-income nations, England’s post-pandemic recovery for hip/knee replacements was slower than Spain, Finland, Italy, Portugal, Sweden, and Norway. “Fewer beds, lower numbers of key staff” explicitly named as causal factors.
NHS RN seniority → mortality reduction (dose-response)	A senior RN (Band 7–8) had 2.2 times the mortality-reducing impact of a Band 5 RN. Pay suppression drives experienced staff out; junior replacements are not equivalent.

---

8. Operational Productivity: Theatre Utilisation, Cases Per List, and the Staffing Paradox

Theatre Utilisation: 38% of Lists Underused Before the Pandemic

An NHS Improvement audit in 2019 found that 38% of theatre lists were underutilised, with unused theatre time estimated to cost the NHS approximately £400 million annually. NHS England’s 2024/25 operational planning guidance set a target of making “significant improvement towards” 85% theatre utilisation — not that the target was being met.

🏥 A note on the metric: The NHS’s “capped theatre utilisation” (CTU) measure in the Model Hospital database is calculated in a mathematically invalid way (Pandit et al., British Journal of Anaesthesia, 2023). The underutilisation problem is real, but the 85% target should be treated as directionally correct rather than a precise comparable benchmark.

Cases Per List: Team Stability Is the Statistically Proven Driver

A study of 255,757 procedures across 38 UK hospitals found that switching between different procedure types on a list increased operative duration by an average of 6.48%. A systematic review of 76 studies concluded that employing specialised and stable teams in dedicated operating rooms showed significant improvements in outcomes; disturbances and communication failures negatively affected operative time and surgical safety.

A case-control study of cataract surgery found an odds ratio of 1.7 (95% CI 1.0–3.1) for complications on lists affected by unplanned staff absence — the direct consequence of thin staffing pools with no experienced cover.

The Waiting List Paradox: More Staff, Barely Any Reduction

NHS Staff Growth 2019–2024 +20% FTE workforce increase	Waiting List Change +73% Mar 2020 → Mar 2024 (4.4m → 7.5m)
Elective Recovery Target 20.9% Activity increase vs 2019/20 set for 2024/25 — significantly missed	Actual YoY Gain 2024/25 2.7% Year-on-year acute productivity growth (NHS England)

Important context: The 2.7% year-on-year rise in 2024/25 is one year’s growth. It does not conflict with NHS England’s position that level productivity remained approximately 8% below 2019/20 — a critical stock-versus-flow distinction often muddled in political debate.

Trust leaders surveyed by NHS Providers (May 2024) identified the top barriers to productivity as: delayed discharges (48%), lack of revenue funding (38%), and patient acuity (37%). The two initiatives most cited as improving productivity: reducing agency spend (55%) and workforce retention initiatives (53%). Not technology. Not management restructuring. Both top levers were about stabilising the permanent workforce.

Productivity Driver	Mechanism	Staffing Link
Theatre underutilisation (38% of lists, £400m/yr)	Beds unavailable; staff absent; lists cancelled	Direct
Switching procedures on list (+6.48% time/case)	Fragmented scheduling; no dedicated specialist lists	Direct
Unplanned staff absence → complications (OR 1.7)	Thin staffing pools; no resilience	Direct
+20% staff, waiting list barely reduced	Younger/less experienced workforce; churn; burnout	Direct — consequence of pay suppression
Delayed discharge blocking beds → cancelled lists	Social care cannot absorb medically fit patients	Indirect — social care staffing crisis
Staff burnout and sickness absence (+18% vs pre-pandemic)	Reduced capacity, unplanned leave, reduced effort	Direct — pay dissatisfaction and overwork

---

9. The Causal Chain: How Pay, Staffing, and Staff Effectiveness Connect to Every Outcome

The eight preceding sections share a single causal root. The chain runs in four documented steps: inadequate pay → attrition and vacancies → depleted, less experienced, less effective workforce → worse clinical outcomes across every domain measured.

Link 1: Pay → Dissatisfaction → Intent to Leave

A 2025 cohort study in The Lancet Regional Health — Europe (UK-REACH cohort) found that pay dissatisfaction is strongly associated with attrition intentions across all staff groups. NHS Employers’ analysis shows a Band 7 ward manager suffered a 13.6% real-terms pay decline between 2013 and 2023. Junior doctor pay satisfaction collapsed from 46% in 2020 to 13.6% in 2023.

NHS Pay Review Body’s Own Conclusion (2023)

“An investment in NHS pay, by reducing attrition and staff shortages and supporting service reform, should lead to improved public health outcomes, labour market participation, and higher national income.”

NHS Pay Review Body, 36th Report 2023. HMSO Cm 866. — the statutory advisory body to government on NHS remuneration.

Link 2: Dissatisfaction and Attrition → Vacancies → Agency Dependency

In 2022, a record 170,000 NHS workers left hospital and community health services, including 41,000 nurses. By September 2023 there were 121,070 recorded vacancies including 42,300 nursing vacancies. These vacancies are filled by agency staff at a peak annual cost of £3.5 billion, or by internationally recruited nurses with no institutional knowledge of NHS systems.

Staff leavers (2022) 170,000 Record high; including 41,000 nurses	NHS Vacancies (Sept 2023) 121,070 Including 42,300 nursing and 8,850 doctor vacancies
Leavers for health reasons ×4 Nearly quadrupled in a decade	Agency spend peak £3.5bn 2022/23 — financial cost of vacancy-driven attrition

Link 3: Depleted Experienced Workforce → Reduced Clinical Effectiveness

A statistically significant mortality benefit was found only for permanently employed registered nurses — not for healthcare support workers, and not for agency nurses. A senior Band 7–8 RN had 2.2 times the mortality-reducing impact of a Band 5 entry-level RN. Every experienced nurse driven out by inadequate pay and replaced by an agency worker represents a net reduction in the safety of every patient on that ward.

NHS staff sickness absence is 18% higher than pre-pandemic levels, with over a quarter of days lost attributable to anxiety, stress, and mental health — the direct product of overwork, understaffing, and persistent pay suppression.

Link 4: Reduced Effectiveness → Every Outcome Measured

OECD cross-national (26 countries)	1% increase in nurse staffing density → 0.65% reduction in AMI mortality; 0.80% reduction in ischaemic stroke mortality. Sweden and Denmark show the highest system-level benefits.
Cancer outcomes (EUROCARE-6)	Sweden records 46.5% five-year ovarian cancer survival. UK: 36.2%. Lung cancer: Sweden 19.5%, UK 13.3%. Persistent, 30-year gap consistent with structural staffing differences.
AMI 30-day mortality (Sweden vs UK)	Sweden 8.4% vs UK 9.7% — registry data from 391,077 UK and 119,786 Swedish patients, 2004–2010.

The Chain, Summarised

A Pay suppressed in real terms 2010–2023Band 7: −13.6% real terms. Junior doctor pay satisfaction: 46% → 13.6%. 31 studies confirm poor pay → poor retention.

↓

B Record attrition and vacancy accumulation170,000 leavers in 2022; 121,070 vacancies (September 2023); leavers for health reasons ×4 in a decade.

↓

C Experienced workforce depleted; agency and international fillAgency spend peaks at £3.5bn. 42% of new nurses non-UK national (2023 vs 21% in 2018). Band 7–8 RN has 2.2× impact of Band 5. Theatre teams destabilised.

↓

D Sickness absence, burnout, and reduced discretionary effortNHS sickness absence 18% above pre-pandemic. Anxiety/stress = 25% of absence. 60%+ clinicians worn out daily. Only 34% believe teams adequately staffed.

↓

E Clinical effectiveness and throughput reduced+20% NHS headcount; output per head falls. 38% of theatre lists underutilised. Productivity 8% below pre-pandemic despite larger workforce.

↓

F Worse outcomes across every domainTreatable mortality above Western peers. Cancer survival below Nordic comparators. AMI mortality higher than Sweden. Waiting list ~7.4m. Negligence £3.1bn.

This chain is not a hypothesis. Each link is supported by operational data. The NHS Pay Review Body — the statutory body advising government on NHS remuneration — has itself concluded that investment in pay would produce improved patient outcomes. The only question remaining is whether policymakers choose to act on the evidence they already have.

---

10. The False Economy: What the NHS Actually Spends on the Consequences

Cost Category	Annual Figure	Causal Link to Staffing Deficit
Clinical negligence pay-outs (2024/25)	£3.1bn	Strong — patient safety failures linked to staffing levels
Agency staff spend (2024/25)	£2.07bn	Direct — agencies fill gaps from pay-driven vacancies
Bank staffing (NHS flexible workers)	~£2–3bn est.	Direct — same structural cause as agency spend
Projected negligence pay-outs (by 2029/30)	>£4bn p.a.	Trajectory continues without structural reform
Total negligence liability (balance sheet, March 2025)	~£60bn	Accumulated years of system failure — largely avoidable harm

The annual consequence cost — agency spend plus negligence pay-outs — is already running at over £5 billion per year. The entire NHS nursing pay bill could be increased by 10% for approximately £2–3 billion per year — less than the agency spend and negligence claims combined. The NHS is spending more on the consequences of understaffing than it would cost to significantly improve permanent staffing levels.

Conclusion: A False Economy With a Human Cost

This three-part series has told a coherent and uncomfortable story. Part 1 showed the UK trains, employs and pays fewer healthcare staff than comparable nations. Part 2 showed the money not spent on staff has been absorbed by non-staff costs, with a combined premium over Scandinavian systems of up to £60 billion per year.

Part 3 shows what happens downstream. Treatable mortality above Western peers. Cancer survival below Nordic countries. Heart attack mortality higher than Sweden. Elective waiting lists of 7.3–7.4 million. Clinical negligence costs of £3.1 billion per year against a £60 billion total liability. Agency spend peaked at £3.5 billion. And an operational productivity crisis: 38% of theatre lists underutilised, £400 million in wasted theatre time annually, a waiting list that barely moved despite a 20% workforce increase.

The statistical correlations between staffing and outcomes are not speculative. A 1% increase in nurse staffing density reduces acute cardiac and stroke mortality by 0.65–0.80%. An extra RN shift reduces ward-level mortality odds by 9.6%. Senior experienced RNs have more than twice the mortality-reducing impact of junior nurses. Section 9 traces the complete causal chain: pay suppression → attrition → vacancies → agency reliance → depleted experienced workforce → worse clinical outcomes. The NHS Pay Review Body itself has concluded that investing in pay would improve patient outcomes.

The question is no longer whether we can afford to invest properly in NHS staffing. The operational data asks a more pointed question: can we afford not to?

Key Sources & Verified References

1. OECD / European Commission (2024). Health at a Glance: Europe 2024. doi.org/10.1787/b3704e14-en
2. OECD (2025). Health at a Glance 2025. doi.org/10.1787/8f9e3f98-en
3. Nuffield Trust (2024). Still waiting: Is it just England that still has a backlog problem? nuffieldtrust.org.uk
4. Nuffield Trust (2024). Mortality rates. nuffieldtrust.org.uk/resource/mortality-rates
5. Propper, C. et al. (2023). BMJ Quality & Safety. PMC10176371
6. Dall’Ora, C. et al. (2024). JAMA Network Open. PMC11333978
7. Dall’Ora, C. et al. (2023). Human Resources for Health. PMC10116759
8. Labbé, V. et al. (2018). ScienceDirect
9. NHS Resolution (2025). resolution.nhs.uk
10. National Audit Office (2025). nao.org.uk
11. House of Commons Public Accounts Committee (2025). publications.parliament.uk
12. House of Commons Library (2025). commonslibrary.parliament.uk
13. EUROCARE-6 / OECD (2024–25). OECD.org (PDF)
14. Coleman, M. et al. (2011). PMID 21183212
15. Jernberg, T. et al. (2015). PMC4528190
16. OECD (2024). oecd.org
17. King’s Fund (2025). kingsfund.org.uk
18. Pandit, J.J. et al. (2023). PMC10308435
19. Institute for Fiscal Studies (2025). ifs.org.uk
20. NHS England (2025). england.nhs.uk
21. ONS (2025). ons.gov.uk
22. Agyemang, C. et al. / UK-REACH (2025). PMC12541634
23. NHS Employers (2023). nhsemployers.org
24. Khamisa, N. et al. (2020). PMC7375434
25. NHS Pay Review Body (2023). assets.publishing.service.gov.uk (PDF)